Citing COVID-19 disruptions, Eiger BioPharmaceuticals (NASDAQ:EIGR) announces that enrollment in its Phase 3 D-LIVR
study evaluating the combination of lonafarnib and ritonavir with or
without PEGylated interferon-alfa-2a in patients with chronic hepatitis D
virus (HDV) infection will not be completed until sometime in 2021. It
says it has enough product to complete the trial.
It is also supplying Peginterferon Lambda and
helping with protocol design in multiple studies in COVID-19 patients.
Preclinical results were apparently encouraging, demonstrating “potent”
antiviral effects against influenza, SARS coronavirus, rotavirus,
norovirus, and reovirus.
Shares up 6% after hours.
https://seekingalpha.com/news/3557537-coronavirus-pandemic-issues-delay-key-eiger-biopharma-study
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.